Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 17/20 | 0.64 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 0.64 |
| ▸ | EIF2AK1 | Q9BQI3 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23042872 | 0.87 | EIF2AK3 (0.70) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL868275 | 0.84 | EIF2AK3 (0.77) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042910 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042883 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042858 | 0.84 | EIF2AK3 (0.65) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042849 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042851 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042882 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL23042954 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL29911557 | 0.84 | EIF2AK3 (0.64) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | claimed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041976-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348584-A1 | PERK INHIBITING INDOLINYL COMPOUNDS | ATF4, MAP3K10, EEF2K | EIF2AK3 85/4885RIPK1 170/4885CYP3A4 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.